Stocktoria
Korro Bio, Inc. KRRO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-10-03
Korro Bio, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $6.4M | $2.3M | $0 | — | — |
| R&D expense | $65.6M | $63.6M | $57.2M | — | — |
| Operating income | -$121.9M | -$91.9M | -$84.5M | — | — |
| Income tax | $637,000 | $141,000 | $27,000 | $0 | $0 |
| Net income | -$117.3M | -$83.6M | -$81.2M | — | — |
| EPS (diluted) | $-12.48 | $-9.37 | $-53.08 | — | — |
| Operating cash flow | -$78.6M | -$60.1M | -$67.3M | — | — |
| Free cash flow | -$79.1M | -$78.0M | -$75.1M | — | — |
| Cash & equivalents | $21.8M | $55.6M | $166.2M | $41.7M | $39.7M |
| Total assets | $113.5M | $226.2M | $221.7M | $46.3M | $79.4M |
| Total liabilities | $62.1M | $65.8M | $51.8M | $9.6M | $34.0M |
| Shareholders' equity | $51.4M | $160.4M | $169.9M | -$153.3M | -$135.4M |
Source: SEC EDGAR filings · CIK 0001703647 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.